Lv34
310 积分 2023-05-13 加入
Serplulimab With Chemotherapy in Extensive-Stage SCLC
1天前
已完结
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
16天前
已完结
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
16天前
已完结
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
16天前
已完结
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
16天前
已完结
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
16天前
已完结
Serplulimab With Chemotherapy in Extensive-Stage SCLC
16天前
已完结
Characterization and exploration of an artifact in the reducing capillary electrophoresis-sodium dodecyl sulfate analysis of the ‘me-too’ drug zuberitamab related to rituximab
16天前
已完结
Future direction of total neoadjuvant therapy for locally advanced rectal cancer
18天前
已完结
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
22天前
已完结
皖公网安备34019202002308
